What Happened
- An international study, published in the journal Nature in February 2026, identified the brain's Somato-Cognitive Action Network (SCAN) as a key region implicated in Parkinson's disease pathophysiology.
- The study involved analysis of brain imaging data from over 800 participants across multiple institutions in the United States and China, led by Changping Laboratory in collaboration with Washington University School of Medicine in St. Louis.
- A small clinical trial of 18 patients showed that transcranial magnetic stimulation (TMS) targeted at SCAN regions resulted in a 56% symptom improvement response rate, compared to 22% in a control group receiving stimulation at adjacent brain areas — a 2.5-fold increase in efficacy.
- The research reveals that Parkinson's disease is associated with hyperconnectivity between SCAN and the subcortex, the brain region responsible for emotion, memory, and motor control.
Static Topic Bridges
Parkinson's Disease and Neurodegeneration
Parkinson's disease is a progressive neurodegenerative disorder characterised by the loss of dopamine-producing neurons in the substantia nigra pars compacta, a region in the midbrain. Dopamine is a key neurotransmitter involved in coordinating smooth and controlled movements; its depletion causes the hallmark symptoms of tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Motor symptoms typically become evident only after 60–80% of dopaminergic neurons have already been lost, making early detection difficult. The disease affects an estimated 10 million people globally, with India having one of the largest burdens in Asia.
- Parkinson's disease is the second most common neurodegenerative disorder globally after Alzheimer's disease.
- Alpha-synuclein protein aggregation (Lewy bodies) and mitochondrial dysfunction are central to the pathogenesis.
- Current treatments primarily manage symptoms via dopamine replacement (e.g., Levodopa) but do not halt disease progression.
- Deep brain stimulation (DBS) is an established surgical treatment targeting basal ganglia circuits.
Connection to this news: The SCAN network's selective connectivity to substantia nigra and all known deep brain stimulation targets makes it a precision entry point for non-invasive therapies; the new study demonstrates that targeting SCAN via TMS can significantly reduce tremors and instability without surgery.
The Somato-Cognitive Action Network (SCAN) and Brain Architecture
The SCAN, first described in a 2023 Nature paper, is a distributed brain network that interleaves with the traditional motor cortex (M1). Unlike effector-specific motor regions that control discrete body parts (hands, feet, mouth), SCAN integrates whole-body action planning with cognitive and autonomic functions. It connects the primary motor cortex to the cingulo-opercular network and exhibits strong connectivity to subcortical structures including the basal ganglia and substantia nigra — precisely the circuits disrupted in Parkinson's disease. The new 2026 study established that Parkinson's disease should be reconceptualised as a "SCAN disorder" rather than purely a motor system failure.
- SCAN regions in M1 are identified by decreased cortical thickness and distinct functional connectivity patterns.
- All established Parkinson's disease deep brain stimulation targets are selectively connected to SCAN, not to effector-specific motor regions.
- The new study found hyperconnectivity between SCAN and subcortex as the neural signature of Parkinson's pathology.
- SCAN has also been implicated in other movement disorders such as focal dystonia.
Connection to this news: Understanding SCAN as the hub of Parkinson's pathology allowed researchers to design TMS protocols that outperformed non-targeted stimulation by 2.5-fold, offering a potential non-invasive treatment pathway.
Transcranial Magnetic Stimulation (TMS) as a Neuromodulation Therapy
Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation technique that uses rapidly changing magnetic fields to induce electrical currents in targeted cortical regions, modulating neuronal activity without surgery or anaesthesia. It has regulatory approval in several countries for treatment-resistant depression and is increasingly being studied for neurological conditions including Parkinson's disease, epilepsy, and stroke rehabilitation. Unlike deep brain stimulation (DBS), which requires surgical implantation of electrodes, TMS is outpatient-based and reversible, making it highly attractive for chronic conditions.
- TMS works on the principle of electromagnetic induction (Faraday's law): a magnetic coil placed near the scalp generates a brief magnetic pulse that induces a cortical current.
- Repetitive TMS (rTMS) is used therapeutically — high-frequency rTMS (>5 Hz) is excitatory; low-frequency rTMS (≤1 Hz) is inhibitory.
- The SCAN-targeted TMS trial achieved a 56% response rate vs 22% in controls over a two-week protocol.
- The technique is particularly promising for Parkinson's as it allows region-specific targeting without the risks of invasive surgery.
Connection to this news: The SCAN study represents the first systematic mapping of a precise brain-network target for TMS in Parkinson's disease, converting what was previously a diffuse therapy into a guided, precision treatment with significantly improved outcomes.
Key Facts & Data
- SCAN = Somato-Cognitive Action Network; first described in Nature, 2023
- Study published in Nature, February 2026; led by Changping Laboratory, China and Washington University School of Medicine, St. Louis
- Imaging data collected from over 800 participants across US and China
- Clinical trial: 18 SCAN-targeted TMS patients vs 18 controls; 56% vs 22% response rate
- Improvement factor: 2.5-fold increase in TMS efficacy when SCAN-targeted
- Parkinson's disease affects ~10 million people globally; second most common neurodegenerative disorder
- 60–80% of substantia nigra neurons are lost before motor symptoms become clinically apparent
- SCAN hyperconnectivity with subcortex identified as a neuroimaging biomarker of Parkinson's disease